Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis by Li-Jie Yin et al.
Yin et al. Multidisciplinary Respiratory Medicine 2013, 8:21
http://www.mrmjournal.com/content/8/1/21ORIGINAL RESEARCH ARTICLE Open AccessUtilization of PET-CT in target volume delineation
for three-dimensional conformal radiotherapy in
patients with non-small cell lung cancer and
atelectasis
Li-Jie Yin1*, Xiao-Bin Yu2, Yan-Gang Ren3, Guang-Hai Gu1, Tian-Gui Ding1 and Zhi Lu1Abstract
Background: To investigate the utilization of PET-CT in target volume delineation for three-dimensional conformal
radiotherapy in patients with non-small cell lung cancer (NSCLC) and atelectasis.
Methods: Thirty NSCLC patients who underwent radical radiotherapy from August 2010 to March 2012 were
included in this study. All patients were pathologically confirmed to have atelectasis by imaging examination.
PET-CT scanning was performed in these patients. According to the PET-CT scan results, the gross tumor volume
(GTV) and organs at risk (OARs, including the lungs, heart, esophagus and spinal cord) were delineated separately
both on CT and PET-CT images. The clinical target volume (CTV) was defined as the GTV plus a margin of 6-8 mm,
and the planning target volume (PTV) as the GTV plus a margin of 10-15mm. An experienced physician was
responsible for designing treatment plans PlanCT and PlanPET-CT on CT image sets. 95% of the PTV was
encompassed by the 90% isodose curve, and the two treatment plans kept the same beam direction, beam
number, gantry angle, and position of the multi-leaf collimator as much as possible. The GTV was compared using a
target delineation system, and doses distributions to OARs were compared on the basis of dose-volume histogram
(DVH) parameters.
Results: The GTVCT and GTVPET-CT had varying degrees of change in all 30 patients, and the changes in the GTVCT
and GTVPET-CT exceeded 25% in 12 (40%) patients. The GTVPET-CT decreased in varying degrees compared to the
GTVCT in 22 patients. Their median GTVPET-CT and median GTVPET-CT were 111.4 cm
3 (range, 37.8 cm3-188.7 cm3) and
155.1 cm3 (range, 76.2 cm3-301.0 cm3), respectively, and the former was 43.7 cm3 (28.2%) less than the latter. The
GTVPET-CT increased in varying degrees compared to the GTVCT in 8 patients. Their median GTVPET-CT and median
GTVPET-CT were 144.7 cm
3 (range, 125.4 cm3-178.7 cm3) and 125.8 cm3 (range, 105.6 cm3-153.5 cm3), respectively,
and the former was 18.9 cm3 (15.0%) greater than the latter. Compared to PlanCT parameters, PlanPET-CT parameters
showed varying degrees of changes. The changes in lung V20, V30, esophageal V50 and V55 were statistically
significant (Ps< 0.05 for all), while the differences in mean lung dose, lung V5, V10, V15, heart V30, mean esophageal
dose, esophagus Dmax, and spinal cord Dmax were not significant (Ps> 0.05 for all).
Conclusions: PET-CT allows a better distinction between the collapsed lung tissue and tumor tissue, improving the
accuracy of radiotherapy target delineation, and reducing radiation damage to the surrounding OARs in NSCLC
patients with atelectasis.
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Radiation is one of the important means for the treatment
of non-small cell lung cancer NSCLC. In the process of
radiotherapy, target area sketch is very important, and it
has important significance in the treatment of patients with
curative effect and prognosis. Most of the radiation treat-
ment planning system is based on Computed Tomography
(CT) image as a target area sketching and dose calculation
basis. However, when NSCLC patients have atelectasis or
obstructive pneumonia, it is difficult to distinguish the
boundaries between incompletely expanded lung tissue and
tumor tissue by conventional CT, which often results in in-
accurate target delineation. As a consequence, insufficient
dose coverage of the target volume or too much damage to
normal tissue is caused. The advent of Positron emission
tomography-Computed Tomography (PET-CT) can help
overcome this problem. PET-CT is a fusion of functional
information got by PET and anatomic information got by
CT [1-3]. PET-CT can effectively identify the boundary be-
tween atelectasis region and lung cancer, make radiation
target area precision, avoid unnecessary radiation injury
and reduce radiation complications, thereby improving the
radiation effect. The studies of Balogh et al. [4]. have
shown that PET-CT imaging avoided the CT miscarriage
of justice for tumor obstructive pneumonia or atelectasis
organization, so that the gross tumor volume (GTV)
narrowed, and found the transfer of lymph nodes which
were not founded on CT, so that the GTV increased.
Hoseok et al. [5] and Wang et al.[6] research results show
that based on the PET - CT radiation plan can improve
the outline of the GTV, helps to reduce the high dose lung
and esophageal illuminated doses, may reduce the lungand esophageal radiation related to toxic reaction and im-
prove the patient's quality of life, and in the same toxic re-
action of cases is expected to further improve the target
dose, improving the local control rate. The research indi-
cates that the PET-CT improves the accuracy of the cli-
nical stage, provides the basis for patients to choose the
correct treatment approach, avoids the treatment select
error induced by the mistakes of stage. At the same time,
PET-CT can make target area sketch more accurate, better
protect surrounding normal tissues, enhance the curative
effect and reduce the radiation complications, thereby im-
proving the patient's quality of life (Tables 1, 2 and 3).
In this study, we retrospectively analyzed the PET-CT
imaging data for 30 NSCLC patients with atelectasis
who underwent three-dimensional conformal radiother-
apy and investigated the utilization of PET-CT in target
volume delineation in these patients.
Methods
Clinical data
Thirty NSCLC patients who underwent PET-CTat the First
Affiliated Hospital of Dalian Medical University from Au-
gust 2010 to March 2012 were included in this study. All
patients were pathologically confirmed to have atelectasis.
There were 19 males and 11 females. They ranged in age
from 54 to 87 years, with a median age of 71 years. Of all
patients, 20 had squamous cell carcinoma, 8 had adenocar-
cinoma, and 2 had adenosquamous carcinoma; 14 had
TNM stage IIIA disease and 16 had stage IIIB disease. In-
clusion criteria were: NSCLC patients who were willing to
undergo radical three-dimensional conformal radiotherapy;
those with lesions detectable by CT or other imaging mo-
dalities; histologically or cytologically confirmed NSCLC;
standardized uptake value (SUV) ≥ 2.5; KPS score ≥ 70
points; and no pericardial effusion.
Equipment and reagents
The Biograph 64 PET/CT system (number of slices = 64;
number of detector rings = 39; Siemens, USA) equipped
with the RDS Eclipse cyclotron was used in this study.
18F-fluorodeoxyglucose (FDG) with a radiochemical
purity of > 96% was used.
PET-CT procedure
All patients were asked to fast for 6 h. Prior to the PET-CT
procedure, blood glucose levels were determined. 18F-FDG
was then intravenously injected at a dose of 0.15 mCi/kg in
patients whose blood glucose levels were in the normal
range. Examinations started 60 min after injection, which
consisted of a spiral CT scan followed by a PET scan during
quiet breathing. CT data were used for attenuation correc-
tion of PET images. Images were then reconstructed using
iterative methods, followed by multi-slice and multi-frame
imaging. PET image reconstruction parameters were: slice
Table 2 GTV obtained from CT and PET-CT images in 30 patients
GTV (cm3) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
CT 301.0 76.2 134.6 131.6 102.1 146.3 98.2 178.3 153.5 165.2 167.8 214.6 156.7 108.5 101.2 245.7
PET-CT 105.8 37.8 95.4 122.7 72.7 107.2 71.6 125.6 128.7 100.7 135.7 100.4 146.2 101.4 93.5 168.1
GTV (cm3) 17 18 19 20 21 22 23 24 25 26 27 28 29 30
CT 108.9 257.4 192.4 101.6 106.8 163.7 144.7 114.8 105.6 131.3 106.5 153.5 121.9 128.4
PET-CT 99.4 109.1 188.7 96.5 100.4 142.9 149.9 125.4 136.4 148.2 131.4 178.7 134.1 153.8
GTV Gross Tumor Volume, CT Computed Tomography, PET-CT Positron Emission Tomography-Computed Tomography.
Table 3 Dose-volume histogram parameters for
PlanCTand PlanPET-CT
Parameter PlanPET-CT PlanCT t P
Lungs
V5 (%) 46.2 ± 22.3 46.4 ± 22.5 −0.866 0.394
V10 (%) 37.6 ± 19.1 37.9 ± 19.6 −1.738 0.089
V15 (%) 26.7 ± 11.9 27.3 ± 15.4 −0.938 0.352
V20 (%) 18.1 ± 9.6 19.6 ± 10.2 −2.108 0.040
V30 (%) 13.2 ± 7.4 14.8 ± 8.5 −2.082 0.042
MLD (Gy) 13.1 ± 4.9 13.9 ± 5.3 −1.918 0.062
Heart
V30 (%) 20.5 ± 17.4 21.6 ± 19.2 −0.676 0.502
MHD (Gy) 15.8 ± 9.1 16.7 ± 10.3 −0.659 0.512
Esophagus
V50 (%) 19.6 ± 15.1 24.5 ± 18.4 −2.326 0.029
V55 (%) 15.4 ± 13.8 20.7 ± 17.6 −2.366 0.022
Dmax (Gy) 61.2 ± 10.2 61.7 ± 12.1 −0.083 0.936
Spinal cord
Dmax (Gy) 40.3 ± 10.9 43.2 ± 11.5 −1.892 0.065
Dmax maximum dose, MHD Mean Heart Dose, MLD Mean Lung Dose, Vx the
percentage volume of organ receiving X Gy of dose, MLD Mean Lung Dose,
MHD Mean Heart Dose, Dmax maximum dose.
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168 × 168, slice thickness for CT image reconstruction =
5 mm, and cross-sectional resolution = 512 × 512. Finally,
PET and CT data were transferred to the ADAC
Pinnacle3TPS workstation where the data sets were fused
automatically.
Target volume delineation
The fused data sets were transferred to the Elekta
TOMCON workstation for delineation of target volumes.
(1)Gross tumor volume (GTV): The GTV refers to
clinically or radiologically demonstrable extent and
location of tumors, including primary pulmonary
lesions and metastatic lymph nodes. Lymph nodes
with a short-axis diameter ≥ 1 cm were considered
metastatic lymph nodes. Contours of primary
pulmonary lesions and metastatic lymph nodes were
first defined based on CT images on lung window
(window width = 1600 Hu, window level = -600 Hu)
and mediastinal window (window width = 400 Hu,
window level = 20 Hu) settings to obtain GTVCT,
then based on PET-CT fusion images (also including
primary lesions and positive lymph nodes) to obtain
GTVPET-CT. The threshold of 42% of maximum
SUV (SUVmax) was used for tumor delineation.
GTVCT and GTVPET-CT values were calculated
automatically on the Elekta TOMCON workstation.
(2)Clinical target volume (CTV): The CTV includes
the GTV and the range of subclinical lesions. In this
study, a uniform margin of 8 mm was added around
the GTV in adenocarcinoma cases, 6 mm in
squamous cell carcinomas, and 6-8 mm in
adenosquamous carcinoma cases depending on
specific situations to form the CTV.
(3)Planning target volume (PTV): The PTV takes into
consideration uncertainties caused by physiological
displacement of organs, patient movements, and set-up
errors that occur during each daily delivery of radiation.
Internal target volume (ITV) was used to assess
physiological displacement of organs, including the PTV
and a margin compensating for daily positioning errors
and internal motion of organs. The ideal CTV should
result in the highest probability of CTV coverage, thusensuring exposure of the CTV to maximum prescribed
dose irradiation in each fraction of radiation. In this
study, the PTV was defined by adding a margin of 10-
15mm to the GTV.
Delineation of organs at risk (OARs)
(1)Lungs: automatically delineated on the Elekta
TOMCON workstation and then manually modified
to exclude the trachea and bronchi.
(2)Heart: delineated from the bottom of the aortic arch
to the bottom of the heart.
(3)Esophagus: delineated from the level of the cricoid
cartilage to the area above the esophagogastric
junction.
(4)Spinal cord: delineated slice by slice after adjusting
CT window width and level to clearly demonstrate
the spinal cord.
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Treatment planning was performed using the Elekta Pre-
cise Plan treatment planning system.
The PTVCT and PTVPET-CT were defined by adding a
margin of 1.0-1.5 cm to the GTVCT and GTVPET-CT. An
experienced physician was responsible for designing
three-dimensional conformal radiotherapy treatment
plans PlanCT and PlanPET-CT on CT image sets. 95% of the
PTV should be encompassed by the 90% isodose curve,
and the two treatment plans should keep the same beam
direction, beam number, gantry angle, and position of the
multi-leaf collimator as much as possible. The prescribed
dose was 2 Gy per daily fraction, 5 days per week, to a
total dose of 60 Gy in 30 fractions. Dose constraints to
OARs were lung V20 < 35%, heart D1/3 < 50 Gy, spinal
cord Dmax< 45Gy, and esophagus Dmax< 60Gy.
Main indicators and parameters
(1)GTVCT and GTVPET-CT calculated automatically on
the workstation;
(2)Dose-volume histogram (DVH) parameters,
including mean lung dose (MLD), lung V5, V10, V15,
V20 and V30, mean heart dose (MHD), heart V30,
esophageal V50 and V55, esophageal Dmax, and
spinal cord Dmax.
Statistical analysis
Statistical analysis was performed using SPSS 19.0 soft-
ware. Comparisons between two groups were performedFigure 1 Comparison between conventional CT and PET-CT image. A:
between incompletely expanded lung tissue and tumor tissue with conseq
metabolic activity indicated the presence of tumors. The target volume wa
conventional CT image, the mediastinal lymph node had a short-axis diam
On PET-CT image, the mediastinal lymph node showed high metabolic actusing the t-test. Data were expressed as mean ± standard
deviation (SD). P <0.05 was considered statistically
significant.Results
GTV
The GTVCT and GTVPET-CT had varying degrees of
change in all 30 patients, and the changes in GTVCT and
GTVPET-CT exceeded 25% in 12 (40%) patients.
The GTVPET-CT decreased in varying degrees com-
pared to the GTVCT in 22 patients. Their median
GTVPET-CT and median GTVPET-CT were 111.4 cm
3
(range, 37.8 cm3-188.7 cm3) and 155.1 cm3 (range, 76.2
cm3-301.0 cm3), respectively, and the former was 43.7
cm3 (28.2%) less than the latter.
The GTVPET-CT increased in varying degrees com-
pared to the GTVCT in 8 patients. Their median
GTVPET-CT and median GTVPET-CT were 144.7 cm
3
(range, 125.4 cm3-178.7 cm3) and 125.8 cm3 (range,
105.6 cm3-153.5 cm3), respectively, and the former was
18.9 cm3 (15.0%) greater than the latter.
The main reason for the decrease in the GTVPET-CT rela-
tive to the GTVCT is that PET-CT allowed distinguishing
tumor tissue from collapsed lung tissue based on their dif-
ference in functional metabolism and reducing the target
volumes (Figure 1A and B). In contrast, it was difficult to
distinguish the boundaries between incompletely expanded
lung tissue and tumor tissue by conventional CT, which
resulted in excessive target delineation.By conventional CT, it was difficult to distinguish the boundaries
uent excessive target delineation. B: By PET-CT, the areas of high
s obviously smaller than that on conventional CT image. C: On
eter of 4.36 mm and was not considered a metastatic lymph node. D:
ivity and was considered a metastatic lymph node.
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relative to the GTVCT is that PET-CT allowed detecting
metastatic lymph nodes that could not be identified by
conventional CT and increasing the target volumes
(Figure 1C and D).
OARs
Compared to PlanCT parameters, PlanPET-CT parameters
showed varying degrees of change. The changes in lung
V20, V30, esophageal V50 and V55 were statistically sig-
nificant (Ps< 0.05 for all), while the differences in MLD,
lung V5, V10, V15, heart V30, MHD, esophageal Dmax,
and spinal cord Dmax were not statistically significant
(Ps> 0.05 for all).
Discussion
Generally, three-dimensional conformal radiotherapy treat-
ment planning is based on CT images; however, the infor-
mation provided by CT data often cannot meet the
requirements of target volume delineation [7]. In recent
years, PET-CT has been increasingly used in clinical prac-
tice to delineate the target volumes for radiotherapy of lung
cancer. PET-CT has an accuracy superior to that of con-
ventional CT and other imaging modalities. Deniaud-
Alexandre et al. [8] delineated the GTV in 92 NSCLC pa-
tients by PET-CT and found that the GTVPET-CT was re-
duced in 23% of the patients and increased in 26% of cases
compared to GTVCT, and 21 patients had a GTV change of
≥ 25%. In this study, we found that all 30 patients had vary-
ing degrees of changes in the GTVPET-CT and GTVCT, in-
cluding 12 (40%) patients who had a change over 25%. This
result is consistent with those reported by Deniaud-
Alexandre et al. and Ceresoli et al. [9].
Although it is important to meet the requirements of
target dose distribution, serious complications of radi-
ation therapy caused by too large irradiated volume or
too high dose to OARs should also be avoided. A given
radiation treatment plan in which the target irradiation
volume and the PTV fit well and the dose is evenly dis-
tributed is still unacceptable when the dose to OARs ex-
ceeds the tolerable dose of the organ or the irradiated
volume of OARs is too large, because the implementa-
tion of this treatment plan will cause great damage to
normal tissue and serious radiotherapy complications.
Bradley et al. [10] contoured the GTV from the CT and
PET-CT data sets in 26 NSCLC patients and found that,
in three patients with atelectasis, the GTV and PTV
obtained from PET-CT images were significantly re-
duced compared to those obtained from CT images, the
MLD decreased from 14.83 Gy to 12.93 Gy, and lung
V20 decreased from 25.33% to 21.33%. They also discov-
ered that the MLD and mean esophageal dose increased
with the increase in the GTV in 11 patients whose target
volumes increased as a result of additional detection ofmetastatic lymph nodes. Van Der Wel et al. [11]
contoured the target volumes by PET-CT and found that
the GTV of the lymph nodes, lung V20, MLD, esopha-
geal V45 and V55 decreased. At the same level of radi-
ation toxicity, radiation dose and tumor control rate
were improved. As a result, the efficacy of radiation
therapy was enhanced. In the present study, we found
that PlanPET-CT parameters showed varying degrees of
change compared to PlanCT parameters. The changes
in lung V20, V30, esophageal V50 and V55 were statisti-
cally significant (Ps< 0.05 for all), while the differences
in MLD, lung V5, V10, V15, heart V30, MHD, esopha-
geal Dmax, and spinal cord Dmax were not significant
(Ps> 0.05 for all).
Acute radiation-induced lung injury is a kind of
lymphocytic alveolar inflammation caused by direct radi-
ation damage and body’s immune response. The severity
of lung functional injury after radiotherapy is closely re-
lated to the irradiated volume. The dose-volume histo-
gram (DVH) offers a range of physical parameters for
the evaluation of radiotherapy-induced lung injury in
lung cancer patients after three-dimensional conformal
radiotherapy. The V20 is currently the most widely used
parameter for clinical evaluation of treatment plans.
However, the results obtained on factors associated with
acute radiation-induced lung injury are different among
different studies. In a study involving 99 NSCLC patients
performed by Graham et al. [12], univariate analysis
showed that the V20 and MLD were closely associated
with the development of acute radiation-induced lung
injury (grade 2 or higher), and multivariate analysis
showed that the V20 was the only independent predictive
factor for acute radiation-induced lung injury. This re-
sult is consistent with that obtained by Tsujino et al.
[13]. In a study conducted by Zhang et al. [14], univari-
ate analysis indicated that the MLD, mean dose to the
affected lung, and V20 were factors associated with the
development of acute radiation-induced lung injury, and
multivariate analysis indicated that only the mean dose
to the affected lung is the independent risk factor. Stud-
ies performed by Hernando et al. [15], Claude et al. [16],
and Kim et al. [17] demonstrated that the V30 was a fac-
tor associated with the development of acute radiation-
induced lung injury. A recent study by Wang et al. [18]
showed that the V5 is also associated with the develop-
ment of acute radiation-induced lung injury, suggesting
that V5 as a dose-volume constraint should be fully
taken into account in designing radiation treatment
plans. In our study, all PlanPET-CT parameters had vary-
ing degrees of decrease compared to PlanCT parameters,
indicating that delineation of the target volumes for
radiotherapy by PET-CT can help reduce the incidence
of acute radiation-induced lung injury in NSCLC
patients.
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about two weeks after the start of radiotherapy. In recent
years, there have been more and more studies investigating
factors associated with the development of esophageal in-
jury in patients undergoing three-dimensional conformal
radiotherapy for NSCLC, although the parameters used
and the conclusions drawn varied among different studies.
Kim et al. [19] suggested that the V60 was an important
parameter to predict acute radiation esophagitis (grade 3
or higher). Algara et al. [20] found that the V50 was the
most valuable predictor. Topkan et al. [21] indicated that
the V55 was the only relevant dosimetric parameter. More
studies indicated that the V55 was likely to be the most
valuable parameter for predicting acute radiation-induced
esophageal injury. Our results indicated that the decrease
in esophageal V55 obtained using PlanPET-CT was statisti-
cally significant (p < 0.05) compared to that obtained using
PlanCT, suggesting that delineation of the target volumes
for radiotherapy by PET-CT can help reduce the incidence
of acute radiation-induced esophageal injury in NSCLC
patients.
Radiation myelitis is a myelopathy that develops fol-
lowing spinal cord exposure to therapeutic radiation
[22]. Due to the combined effects of a variety of factors,
neuronal degeneration and necrosis occur. The develop-
ment of radiation myelitis is associated with exposure of
normal spinal cord tissue to high-dose radiation [23,24].
In our study, spinal cord Dmax obtained using PlanPET-
CT decreased compared to that obtained using PlanCT,
but the difference was not statistically significant. More
emphasis should be put on the prevention of radioactive
myelitis, and radiation dose to the spinal cord must be
strictly controlled during radiotherapy.
Radiation damage to the heart is mainly manifested as
ECG abnormalities, especially ischemic ST-T changes.
The incidence of heart injury will significantly increase if
1/3 of the heart volume receives 70 Gy, 2/3 of the heart
volume receives 55 Gy, or the whole heart receives 50
Gy. Our study suggests that PET-CT can help protect
from cardiac injury to a certain extent, although the dif-
ference was not obvious between the two groups.
Conclusions
In summary, the results of this study show that PET-CT
fusion image is beneficial to target area sketch in pa-
tients merged with atelectasis of non-small cell lung can-
cer, and optimization of precise radiotherapy planning.
By lowering the irradiation dose of the surrounding nor-
mal lung tissue and avoiding missing the irradiation of
target area, the utilization of PET-CT can reduce the
probability of occurrence of acute radiation-induced
lung injury and acute radiation-induced esophageal in-
jury. Also, the utilization of PET-CT has a protective ef-
fect on the heart and spinal cord. It brings the benefitsto the lung cancer patients. Therefore, we believe that
PET-CT will play more and more important role in
radiotherapy of NSCLC.
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